MicroRNAs and Recent Insights into Pediatric Ovarian Cancers by Jessica C. Francis et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 30 April 2013
doi: 10.3389/fonc.2013.00095
MicroRNAs and recent insights into pediatric ovarian
cancers
Jessica C. Francis1, Nonna Kolomeyevskaya2, Claire M. Mach3, Jennifer E. Dietrich1 and
Matthew L. Anderson1,4,5*
1 Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA
2 Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
3 College of Pharmacy, University of Houston, Houston, TX, USA
4 Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA
5 Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
Edited by:
Jeffrey Toretsky, Georgetown
University, USA
Reviewed by:
David A. Rodeberg, East Carolina
University, USA
Subbaya Subramanian, University of
Minnesota, USA
*Correspondence:
Matthew L. Anderson, Department of
Obstetrics and Gynecology, Baylor
College of Medicine, One Baylor
Plaza, BCM 610, Houston, TX 77030,
USA.
e-mail: matthew@bcm.edu
Ovarian cancer is the most common pediatric gynecologic malignancy. When diagnosed
in children, ovarian cancers present unique challenges that differ dramatically from those
faced by adults. Here, we review the spectrum of ovarian cancers found in young women
and girls and discuss the biology of these diseases. A number of advances have recently
shed significant new understanding on the potential causes of ovarian cancer in this unique
population. Particular emphasis is placed on understanding how altered expression of non-
coding RNA transcripts known as microRNAs play a key role in the etiology of ovarian
germ cell and sex cord-stromal tumors. Emerging transgenic models for these diseases
are also reviewed. Lastly, future challenges and opportunities for understanding pediatric
ovarian cancers, delineating clinically useful biomarkers, and developing targeted therapies
are discussed.
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INTRODUCTION
Adnexal masses are a common cause for the medical evaluation
of young women and girls. Approximately 5–10% of all women
in the United States undergo surgery for an adnexal mass at some
point in their lives (Barakat et al., 2009). In most cases, adnexal
masses in young women are benign cystadenomas that arise either
from the ovary or developmental remnants of paratubal tissue.
However, 2–8% pediatric adnexal masses are ultimately diagnosed
as cancer (Barakat et al., 2009).
CLINICAL SPECTRUM
In contrast to adult ovarian cancers, pediatric ovarian cancers typ-
ically originate in germ cells or stroma rather than epithelia lining
the ovarian surface, distal fallopian tube, or peritoneal implants
of endometriosis. Approximately 40% of ovarian tumors are germ
cell tumors whereas 25% are sex cord-stromal tumors (Barakat
et al., 2009). Germ cell ovarian cancers are a diverse category of
tumors that include both benign and malignant disease. Ovarian
teratomas (“dermoids”) are the most common and perhaps best-
known example of a benign ovarian germ cell tumor. While their
true incidence in the general population is unknown, dermoids
account for approximately 65% of adnexal masses in pediatric
patients presenting for treatment (Ehren et al., 1984). Malig-
nant ovarian germ cell tumors are much less common than their
benign counterparts. Histologically, malignant germ cell tumors
recapitulate rudimentary tissues observed during normal human
development (Table 1). The most common malignant ovarian
germ cell tumor is dysgerminoma (Chieffi et al., 2012). Other germ
cell tumors observed in the ovary include immature teratomas and
endodermal sinus tumors. Combinations of different histologic
elements are frequently observed in the same ovarian tumor. These
“mixed” tumors frequently contain elements of dysgerminoma
(Chieffi et al., 2012).
Ovarian sex cord-stromal tumors are also relatively common
in the pediatric population (Table 1) (Barakat et al., 2009). Gran-
ulosa cell tumors (GCTs) are the most common sex-cord-stromal
tumor. GCTs account for 2–5% of these malignancies regardless of
age at diagnosis. Ovarian GCTS cancers are categorized as either
juvenile or adult type. Juvenile granulosa ovarian cancers (JGCT)
occur mainly in premenarchal girls and comprise roughly 5% of
GCTs (Gell et al., 1998). Adult type granulosa cell cancers (AGCT)
tend to occur in older women but can also occur in girls and
young women. The JGCT and AGCT subtypes are histologically
distinguished by the fact that cells in AGCT exhibit “coffee bean”
nuclei and are often organized into fluid filled structures known
as Call-Exner bodies. Similar features are seen only rarely in JGCT
(Schneider et al., 2005).
Pediatric ovarian cancers frequently present with symptoms,
such as premature menarche, that can be attributed to their ability
to secrete estrogen and other biologically active substances. This
feature reflects the origin of GCTs and sex cord-stromal tumors
in cells involved in the synthesis and secretion of steroid hor-
mones. However, benign ovarian cysts can also be associated with
specific estrogen-induced findings, including the premature devel-
opment of breast tissue, onset of menstruation, and clitoromegaly.
In one study of 34 patients with precocious puberty, ovarian
cysts were responsible for pubertal physical findings in 7% of
young girls (Mitrovic et al., 2006). Depending on the hormonal
www.frontiersin.org April 2013 | Volume 3 | Article 95 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Francis et al. MicroRNAs and pediatric ovarian cancers
Table 1 | Classification of pediatric ovarian tumors.
GERM CELLTUMORS
Teratoma
Dysgerminoma
Yolk-sac tumor
Embryonal carcinoma
Polyembryoma
Choriocarcinoma
Mixed germ cell tumor
SEX CORD-STROMALTUMORS
Granulosa-stromal cell tumors
Adult type
Juvenile type
Thecoma-fibroma tumors
Thecoma
Fibroma-fibrosarcoma
Sclerosing stromal tumor
Sertoli-stromal cell tumors
Sertoli cell tumor
Leydig cell tumor
Retiform
Mixed
Sex cord tumor with annular tubules
Unclassified
Gynandroblastoma
activity of a granulosa cell or Sertoli–Leydig tumor, patients
may present with contrasexual rather than isosexual precocious
puberty. Isosexual precocious puberty in young women is accom-
panied by elevated levels of serum estrogen as well as a failure
to observe a gonadotropin response following GnRH stimula-
tion. Contrasexual precocious puberty is associated with androgen
secretion, results in virilization and can usually be attributed to
Sertoli–Leydig tumors.
INHERITED SYNDROMES
The causes of ovarian cancer in both the adult and pediatric popu-
lations are not yet well understood. However, significant advances
have been recently made in delineating molecular events that
underlie inherited syndromes of ovarian cancer in both the adult
and pediatric populations. In adults, epithelial ovarian cancers
have been associated with dominant negative mutations in gene
products (BRCA1/2) that play a critical role in DNA damage repair
(Pruthi et al., 2010). Recent advances in understanding the biology
of BRCA1/2 have led to the discovery that many high grade serous
ovarian cancers likely originate either in the distal fallopian tube
or at an epithelial transition between the fallopian tube and ovary.
(Auersperg et al., 2008; Crum et al., 2012).
Currently, there is no evidence to indicate that mutations asso-
ciated with epithelial ovarian cancers in adults are causally linked
to pediatric ovarian cancers. Instead, pediatric ovarian cancers
are associated with a number of hereditary and non-hereditary
syndromes distinct from the syndromes of breast/ovarian cancer
linked to BRCA1/2. The first syndrome shown to be associated
with pediatric ovarian cancer is Ollier disease. Ollier disease is
a non-hereditary disorder of the skeleton that is characterized
by cartilaginous implants (enchondromas) in the metaphyseal
portion of long bones (Gell et al., 1998). The estimated preva-
lence of Ollier disease in the U.S. population is roughly 1 per
100,000. Nine cases of juvenile granulosa cell tumor (JGCT) of
the ovary have been reported in individuals with Ollier disease
(Rietveld et al., 2009), a number that is significantly greater than
expected by chance. Very little is currently known about the mech-
anisms linking Ollier disease and ovarian cancer. However, it has
been noted that the ovarian tumors that develop in patients with
Ollier disease are usually unilateral and are frequently noted on
the same side of the body as the patient’s most recently resected
endochondroma (Gell et al., 1998).
Pediatric ovarian cancers have also been reported as part
of the disease spectrum for inherited syndromes of pleu-
ropulmonary blastoma (PPB), multinodular goiter (MNG),
and blepharophimosis-ptosis-epicanthus inversus syndrome
(Crisponi et al., 2001; Doros et al., 2012). Both PPB and MNG
have been previously linked to the same region on human chromo-
some 14q, suggesting a shared genetic etiology (Bignell et al., 1997).
PPB is a rare pediatric mesenchymal thoracic tumor that results
in lesions histologically characterized by immature epithelium and
mesenchymal cells resembling fetal lung. While the exact incidence
of ovarian tumors in patients with familial PPB is unknown, ovar-
ian sex-cord-stromal tumors appear to be a relatively infrequent
manifestation of this syndrome. One recent study has reported
that 9/325 individuals with this syndrome had been diagnosed
with an ovarian sex cord-stromal tumor (Schultz et al., 2011).
Germline mutations in DICER1, a key endonuclease involved
in microRNA (miRNA) processing (see Figure 1), have been
identified in a nearly one-half of children diagnosed with PPB,
including PPB patients previously diagnosed with an ovarian sex-
cord-stromal tumors (Hill et al., 2009). In most cases, the reported
DICER1 mutations are predicted to generate a truncated protein
with impaired function. Similar germline mutations in DICER1
have also been identified in familial syndromes of MNG (Rio Frio
et al., 2011). Like PBB, a subset of familial MNG patients develops
ovarian Sertoli–Leydig cell tumors, a type of ovarian sex cord-
stromal tumor (see Table 1). However, in contrast to the situation
with PPB, the penetrance of Sertoli–Leydig cell tumors in MNG
patients with DICER1 mutations appears to be much higher. This
higher penetrance likely reflects the distinct spectrum of mutations
discovered in the MNG population. MNG-associated mutations
include both missense mutations and in-frame deletions. In par-
ticular, the spectrum of DICER1 mutations in families with MNG
have been predicted to selectively disrupt the PAZ domain of this
gene product, impacting the RNase domains of DICER1 respon-
sible for trimming pre-miRNAs to their mature length (Lau et al.,
2009; Rio Frio et al., 2011). Existing evidence suggests that these
mutations are also associated with an earlier age at onset for
Sertoli–Leydig cell tumors.
MOLECULAR BIOLOGY
A wide range of other strategies in addition to traditional pedigree
studies have been used to advance our understanding of pediatric
ovarian cancers (Table 2). Similar to the work discussed above, this
work points to a key role for non-coding RNA transcripts known as
Frontiers in Oncology | Pediatric Oncology April 2013 | Volume 3 | Article 95 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Francis et al. MicroRNAs and pediatric ovarian cancers
FIGURE 1 | MicroRNA Biogenesis and Function. Most human miRNAs are
initially transcribed as long precursors known as pri-miRNAs. Pri-miRNAs
undergo a series of processing events that ultimately result in the cytoplasmic
release of a mature double-stranded miRNA. Key events in miRNA biogenesis
include active export of pre-miRNAs from the nucleus via a nuclear
membrane complex that includes RANGAP1 and RANBP1. Once within the
cytoplasm, pre-miRNAs undergo endonucleolytic cleavage by DICER1. Recent
evidence now suggests that passenger miRNA strands may actively target
patterns of gene expression rather than undergoing degradation. hAGO2,
human Argonaut; RISC, RNA-induced Silencing Complex.
Table 2 | Recently identified genes of interest in pediatric ovarian
cancers.
Germ cell tumors Sex cord-stromal tumors Borderline tumors
TSPY (human) DICER1 (human) KRAS (human)
c-kit (human) Gct1 (mouse) BRAF (human)
Inhibin-alpha (mouse) Wnt (mouse/human) PIK3CA (human)
SMAD1/5 (mouse) FOXL2 (human) EGFR (human)
PI-3 kinase (mouse/human) PDGFRA (human)
mTORC1 (mouse/human) CTNNB1 (human)
microRNAs (miRNAs) in these diseases. Other studies have impli-
cated a transcription factor known as FOXL2. Many aspects of the
mechanisms by which disruptions in the miRNA expression or
FOXL2 function lead to ovarian cancer remain poorly understood.
DICER1 AND SERTOLI–LEYDIG CELL TUMORS
MicroRNAs are small, highly conserved non-coding RNA tran-
scripts that play a critical role in silencing patterns of gene
expression (Kasinski and Slack, 2010). As genetic elements, miR-
NAs have been previously implicated in the regulation of cellular
differentiation, proliferation, and apoptosis and have been shown
to function as both tumor suppressors and oncogenes (Zhang et al.,
2007). Aberrant miRNA expression has been demonstrated in var-
ious cancers of hematologic, gastrointestinal, genitourinary, pul-
monary, endocrine, neurologic, and dermatologic origin. (Zhang
et al., 2006; Creighton et al., 2010; Medina et al., 2010; Trang et al.,
2010; Iorio and Croce, 2012).
The human genome contains approximately 1000 miRNAs. Of
interest, the genomic loci for more than 50% of miRNAs are found
within the cancer associated genomic regions (CAGR), fragile
sites, regions of loss of heterozygosity, amplification, and viral
integration sites (Zhang et al., 2006). Generally, overexpression
of miRNAs is the result of gene amplification, deregulation of a
transcription factor, or demethylation of CpG islands in the pro-
moter region. In contrast, miRNA down-regulation is guided by
gene deletions, epigenetic silencing, and loss of transcription fac-
tor expression (Corney et al., 2007; Zhang et al., 2007; Mirnezami
et al., 2009; Ruan et al., 2009). One of the proposed mechanisms
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of cancer metastasis is promoter CpG island hypermethylation
that blocks the expression of tumor suppressor miRNAs (Lujam-
bio et al., 2008). In turn, decreased miRNA expression impacts
genes responsible for angiogenesis, invasion, and cell adherence.
These include cadherins, tissue inhibitors of metalloproteinases,
and thrombospondins (Wiemer, 2007).
MicroRNA genes are typically located in the introns of protein-
coding genes, where they are transcribed by RNA polymerase II
either independently or as part of a polycistronic cluster (Bartel,
2004). Initial transcription of most miRNAs results in the creation
of a long primary transcript, known as the pri-microRNA (pri-
miRNA). While still within the nucleus, pri-miRNAs are 5′-capped
and 3′-polyadenylated, after which, they are processed by a 650-
kDa microprocessor complex that includes the ribonuclease III
(RNase III) Drosha and the dsRNA-binding protein DGCR8. Pri-
miRNA processing by Drosha results in a 70-nucleotide hairpin
structures known as pre-microRNAs that are actively transported
to the cytoplasm. Cytoplasmic export is an energy-dependent
process that relies on a nuclear membrane complex and involves
multiple gene products including Exportin 5 (XPO5) and mul-
tiple guanine nucleotide exchange factors such as RANBP1 and
RANGAP1. Once within the cytoplasm, pre-miRNAs are cleaved
by the RNase III endonuclease DICER1. This final processing
step involves the transactivating response RNA binding protein
(TRBP), and results in the release of a mature, double-stranded
miRNA molecule.
Functionally, miRNAs can regulate gene expression by a num-
ber of different mechanisms. In most cases, these involve direct
binding between nucleotides located within the miRNA“seed”and
complementary sequences in the 3′-untranslated region (3′-UTR)
of its target mRNA. In the case of perfect complementary, endonu-
cleolytic cleavage of the mRNA occurs. This is thought to be the
primary mechanism by which miRNAs result in translational inhi-
bition. The ability of miRNAs to induce mRNA degradation has
been shown to depend on their ability to incorporate mRNAs
into the RNA-induced silencing complex (RISC). The RISC is a
multiprotein complex that also contains human argonaute fam-
ily of proteins – hAgo2 – that have endonuclease activity. These
proteins have RNA-binding domains – PAZ and PIWI that resem-
bles ribonuclease H; they bind to single-stranded 3′ end of the
miRNA and 5′ end of the miRNA guide strand. After the passen-
ger strand of the miRNA is degraded, the remaining guide strand
of the mature miRNA directs the RISC complex to the 3′-UTR of
target mRNA.
Alternatively, imperfect complementary between a miRNA and
its target mRNA results in translation repression (Saraiya et al.,
2013). Processing bodies (P-bodies) are recently discovered struc-
tures that store target mRNAs away from ribosomes. There, target
mRNAs undergo enzymatic degradation by decapping enzymes
Dcp1/Dcp2, 5′–3′ exonuclease Xrn1, and de-adenylating enzymes.
Thus miRNAs down-regulate expression of target genes at the level
of translation. Current understanding of key events in miRNA
biogenesis and biology are summarized in Figure 1.
As discussed above, mutations in DICER1 have been implicated
in inherited syndromes of pediatric ovarian cancer. In mammalian
cells, DICER1 plays a key role in final cytoplasmic processing of
pre-miRNAs leading to the release of the mature miRNA. Recently,
investigators have reported that somatic mutations in DICER1 are
frequently observed in ovarian sex cord-stromal tumors (Heravi-
Moussavi et al., 2012). These mutations were found in as many
as 60% of Sertoli–Leydig cell tumors, most frequently impact
nucleotides encoding Asp1709 or Glu1813. These investigators
found similar mutations in DICER1 only rarely in other solid
human tumors, such as endometrial and ovarian cancers (Heravi-
Moussavi et al., 2012). In contrast to the germline mutations
in DICER1 reported in PPB and MNG, the somatic DICER1
mutational “hot-spots” identified in Sertoli–Leydig cell tumors
are located at metal-binding sites critical for miRNA interaction
and cleavage within the RNase IIIb domain of this gene product.
They are predicted to have little or no impact on DICER1’s RNase
IIIa activity, meaning that DICER1 function in these patients is
disrupted rather than lost.
How DICER1 mutations impact the miRNA repertoire of
the cells and tissues in which they are expressed in an impor-
tant question that has yet to be resolved. Profiling of tumors
and lymphoblastoid cell lines derived from patients with MNG
have found evidence for decreased expression of miR-345, let-7a,
miR-99b, miR-133, and miR-194 in common between MNG and
normal-appearing thyroid tissue of patients carrying one of these
mutations. Of these, only miR-345 is highly expressed in normal
thyroid; let-7a has not been previously implicated in thyroid dis-
ease (Rio Frio et al., 2011). Mutations in DICER1 altered the RNase
IIIb activity of DICER1 have also been hypothesized to generate
a bias toward the processing or selection of transcripts that pri-
marily depend on RNase IIIa activity, such as 3′ mature miRNAs.
Until recently, these transcripts, previously known as miR* strands,
were thought to largely lack biologic function (Aktas et al., 2013).
In general, miRNA transcripts located on the 5′ arm of miRNA
precursors (5′ mature miRNAs) were expressed at much greater
abundance in many cells and tissues. A number of other observa-
tions have also suggested that 5′mature miRNAs are preferentially
loaded by DICER1 into the RISC and that this capacity does not
depend on the integrity of its RNase IIIa domain (Risch et al.,
1996; Noland et al., 2011). However, it is now clear that 3′ mature
miRNAs (miR* strands) are also able to target patterns of gene
expression in seed-dependent fashion similar to miRNA guide
strands (Yang et al., 2011). Recent in vitro evidence generated with
genetically modified clones of DICER1 has confirmed that muta-
tions impacting the RNase IIIb domain of DICER1 result in a
near complete loss of 5′ mature miRNAs with little impact on the
expression of 3′ mature miRNAs. Remarkably, mutations in the
RNase IIIa domain of DICER1 had the opposite effect, enriching
the populations of miRNA found in cells for 3′mature transcripts.
Thus, altering the miRNA landscape by selective mutations in
a specific domain of DICER1 could easily lead to an oncogenic
environment with distinct tissue specificities.
FOXL2 AND GRANULOSA CELL TUMORS
Significant progress has also been made in understanding the
molecular basis of human ovarian GCTs using high through-
put sequencing. These studies indicate that juvenile and adult
granulosa cell tumors may be molecularly distinct, despite the
fact that they can share clinical and histologic features. Using
whole-transcriptome paired-end RNA sequencing, Shah et al.
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(2009) recently identified a somatic missense mutation (C to G)
at position 412 of FOXL2, a member of the forkhead-winged-
helix family of transcription factors, in four human ovarian GCTs.
FOXL2 is a transcription factor that plays an important role
in female reproductive tract development and function in both
mouse and humans (Cocquet et al., 2002). In humans, high-
est levels of FOXL2 expression are found in ovarian granulosa
cells with lower levels of expression also observed in ovarian
stroma. Robust FOXL2 expression is also observed in the human
eyelid.
In granulosa cells, FOXL2 functions as a transcriptional repres-
sor, regulating the expression of key gene products important
for granulosa cell function in adult ovary, including steroido-
genic acute regulatory protein (STAR), P450 aromatase and cyclin
D2 (Kuo et al., 2012). In mice, Foxl2 represses the expression
of FSH-dependent genes in granulosa cells (Garcia-Ortiz et al.,
2009). Its disruption results in premature ovarian failure (Uda
et al., 2004). In humans, FOXL2 has been shown to have a
role in regulating ovarian transcription of gonadotropin-releasing
hormone receptor as part of an AP1-SMAD3-SMAD4 complex
(Ellsworth et al., 2003). This latter observation is noteworthy in
that transforming growth factor β (TGF-β) regulates granulosa
cell proliferation in large part by activating SMAD2 and SMAD3
via its cell surface receptor. Defects in TGF-β signaling regu-
lated by crosstalk between ovarian germ cells and stroma are also
commonly observed in ovarian germ cell tumors, which will be
discussed below.
As mentioned above, germline mutations in FOXL2 have been
described in families with blepharophimosis-ptosis-epicanthus
inversus syndrome (Crisponi et al., 2001). This observation is
significant, because ovarian GCTs occur at an increased rate in
a subset of families with this syndrome. Subsequent characteri-
zation of additional specimens identified the same mutation in
86/89 adult granulosa cell tumors (AGCTs), but only 1/10 JGCTs
and 3/14 benign ovarian thecomas. Notably, no evidence for this
mutation was found in 49 specimens representative of other types
of ovarian sex-cord-stromal tumors or 329 unrelated ovarian or
breast tumors of different histologies.
The mechanisms by which position 412 (C to G) mutations
disrupt FOXL2 function and leads to an ovarian sex cord-stromal
tumor are not yet clear. The amino acid residue altered by this
mutation is located on the surface of the forkhead DNA-binding
domain characteristic of this transcription factor, where it appears
to interfere with normal transcriptional activity (Shah et al., 2009).
At least one recent study has found that the patterns of gene expres-
sion in human GCTs are highly enriched for FOXL2 transcriptional
targets (Benayoun et al., 2012). However, the mechanisms by which
clinically relevant mutations in FOXL2 impact transcription in
granulosa or other cells have yet to be precisely demonstrated.
Molecular modeling suggests that this missense mutation fails to
disrupt folding of DNA-binding domain or its ability to inter-
act with DNA (Shah et al., 2009). Furthermore, no differences
were observed in the intracellular localization of mutant FOXL2.
Thus, the mutation associated with GCTs would appear to pro-
mote tumorigenesis by other mechanisms, possibly by altering
FOXL2’s capacity to interact with one or more of its multiple bind-
ing partners. It is also possible that FOXL2 mutations cooperative
with other genetic events even though the protein products gener-
ated by these genes do not directly interact with one another. For
example, monosomy 22, gains of chromosomes 12, 14, and loss of
X have all been reported as recurrent abnormalities in both adult
and JGCTs in humans (Fletcher et al., 1991). The mechanisms by
which these latter genomic imbalances promote the initiation or
progression of GCTs are not known. Although they do not appear
to contribute to a loss of FOXL2 expression in FOXL2 wild-type
AGCT, it is possible that the altered patterns of gene expression
they induce may have a permissive effect for tumorigenesis in the
background of FOXL2 mutations or by altering activity in path-
ways normally regulated by this transcription factor (Geiersbach
et al., 2011).
MOUSE MODELS OF GRANULOSA CELL TUMORS
Due to the relative rarity of pediatric ovarian cancer, obtaining
adequate tissue samples for research purposes can be difficult.
Over the course of the past 20 years, a number of mouse models
for ovarian GCTs have been developed that are potentially use-
ful for understanding these cancers. Granulosa cells are the most
proliferative cells found in the adult mammalian ovary. Perhaps
reflecting this proliferative capacity, ovarian GCTs are relatively
common in many mammalian species. GCTs of the ovary occur
spontaneously in a number of specific inbred strains of mice. At
least one of the loci (Gct1) responsible for these tumors has been
mapped to a 1.31× 106 base pair interval on mouse chromosome
4 (Smith et al., 2012). This region is orthologous to human chro-
mosome 1p36.22 and encodes four known protein-coding gene
products. All four of these gene products appear to be expressed
in normal mouse and human ovary. One (Tnfrsf8) is a member
of the TNF-receptor superfamily known to bind TNF-alpha and
regulates both proliferation and apoptosis. Of note, the genomic
region at 1p36.22 in humans has been previously implicated in dif-
fuse large B-cell lymphomas (Kreisel et al., 2011) and is frequently
lost in both hepatocellular carcinomas (Zhang et al., 2010) and
infiltrating ductal carcinomas of the breast (Hawthorn et al., 2010).
It is not currently known whether the 1p3.22 locus or any of the
genetic elements it encodes contribute to the initiation or metas-
tasis of GCTs. In part, answers to this question have been difficult
to obtain, because the relative rarity of human ovarian GCTs has
precluded adequately powered genome-wide association studies.
Transgenic mice have also emerged as a potential tool for exam-
ining the molecular mechanisms involved in ovarian GCTs. In
general, the transgenic events leading to GCTs in mice disrupt key
pathways regulating granulosa cell proliferation. The first mouse
model for ovarian GCTs was a transgenic knockout of inhibin-
alpha (Matzuk et al., 1992). Inhibin-alpha is a key paracrine
factor synthesized in granulosa cells that is involved in the nor-
mal proliferation of germ cells and somatic cells as well as the
assembly of ovarian follicles in both humans and mice. Ovaries
from inhibin-alpha knockout mice exhibit early follicular recruit-
ment and advanced follicular growth. These phenotypes are due
to a defect in the normal communication between germ cell and
somatic cells. In turn, these defects eventually lead to large ovarian
tumors (Myers et al., 2009). Conditional deletion of Smad1 and
Smad5 in the somatic cells of the ovary of mice has been shown
to also result in metastatic tumors (Pangas et al., 2008). Tumor
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development in these models is suppressed by two functionally
distinct receptors for bone morphogenetic protein (BMP) found
in murine granulosa cells (Edson et al., 2010). Other genetic lesions
that lead to ovarian tumors in mice include the expression of a sta-
ble, active mutant from of CTNNB1 that activates wnt/β-catenin
signaling and produces dysplastic ovarian lesions that eventually
develop into GCTs (Boerboom et al., 2005). Work with these ani-
mals has shown that both k-ras activation and PTEN loss enhance
CTNNB1-induced ovarian tumorigenesis (Richards et al., 2012).
However, mutations that are seemingly unrelated to inhibin sig-
naling pathways also result in GCTs in mice. For example, ovarian
tumors have been found in the ovaries of transgenic mice deficient
for Fancf, a DNA damage repair gene (Bakker et al., 2012).
Importantly, mouse models for GCTs at least partially pheno-
copy human disease. Hyperactivation of PI-3 kinase signaling and
mammalian target of rapamycin complex 1 (mTORC1) are com-
mon features of both human and mouse ovarian GCTs. In both
healthy women and mice, FSH acts via its receptor on the surface of
ovarian granulosa cells to stimulate phosphatidyl inositol 3-kinase
(PI3K)-AKT signaling pathways. In mice, an activating mutation
(H1047R) in PI3KCA coupled with PTEN loss has been recently
shown to be sufficient to induce both ovarian GCTs and serous
ovarian adenocarcinomas in mice (Kinross et al., 2012). Both the
H1047R mutation and PTEN inactivation were required for early,
robust activation of Akt and the development of tumors in these
animals. Pharmacologic mTOR inhibition has been shown to delay
tumor growth and prolong survival in this model. The investi-
gators responsible for this work went on to examine a series of
human ovarian granulosa cell cancers, finding PIK3CA mutations
co-existent with both KRAS and PTEN mutations. Other analyses
of human GCTs have found increased levels of mTOR protein as
well as enhanced expression of the downstream mTOR effectors
RPS6KB1, RPS6, eIF4B, and PPARG relative to normal granulosa
cells (Kinross et al., 2012). These observations suggest that activ-
ity in mTOR pathways are also increased in human GCTs. PI-3
kinase signaling has been recently explored as a potential ther-
apeutic target for human GCTs (Ongeri et al., 2005). However,
preclinical data would suggest that mTOR may not be adequate
as a therapeutic target in this scenario. When everolimus (an
orally administered inhibitor of mTOR) was used to treat a mouse
model [Pten (tm1Hwu/tmiHwu); Ctnnb1 (tm1Mmt/+); Amhr2
(tm3(cre)Bhr/+] in which mTOR, RPS6KB1, eIF4B, and PPARG
are upregulated in tumor cells similar to human GCTs, investi-
gators were unable to fully reverse the molecular consequences
of mTOR activation despite the fact that the use of everolimus
slowed tumor growth (Rico et al., 2012). At least one group has
questioned the relevance of these findings. Bittinger et al. (2009)
recently examined a series of human ovarian GCTs as well as two
cell lines (COV434 and KGN), using direct sequencing to screen
for mutations. Expression of PIK3CA, PIK3R1, and PTEN was
observed in all specimens and neither deletions nor mutations
of the exons known to be “hot spots” for these genes could be
identified in GCTs.
OVARIAN GERM CELL TUMORS
Germ cell tumors account for 15% of malignances diagnosed
in both boys and girls during childhood and adolescence.
Dysgerminomas of the ovary are analogous to testicular semi-
nomas. These tumors originate from the primordial germ cells
(PGC) arrested in their development. Their pluripotency directs
further malignant transformation which mimics embryogenesis:
embryonal carcinoma (EC), teratoma, yolk-sac tumor (YST), and
choriocarcinoma (CH).
The incidence of ovarian dysgerminomas is increasing for rea-
sons that remain unclear (Frazier and Amatruda, 2009). The cell
of origin for all germ cell tumors is currently believed to be an
early germline progenitor known as a PGC. Pediatric germ cell
tumors are widely believed to develop due to dysregulated activity
in the embryonic signaling pathways that regulate PGC differen-
tiation and maturation. Key pathways important in this process
include both Notch- and Hedgehog-regulated signaling. Multiple
components of these pathways have been shown to be aberrantly
activated in subsets of pediatric germ cell tumors (Morichika et al.,
2010). Perhaps the best studied pathway potentially involved in the
pathogenesis of pediatric germ cell tumors is regulated by TGF-β.
Multiple components of the TGF-β and BMP families are robustly
expressed in developing germ cells and somatic cells in both the
male and female gonad (Itman et al., 2006). Significant evidence
has implicated aberrant activation of TGF-β signaling in testicular
germ cell tumors (Dias et al., 2009) Activation of BMP pathways
appears to be most robust in pediatric YSTs (Fustino et al., 2011).
Due to their shared origin in a PGC, the events leading to
ovarian and testicular germ cell tumors are widely assumed to
be similar. However, it is less clear how widely these observations
made in testicular germ cell tumors, such as those described above,
actually apply to germ cell tumors occurring in females. An accu-
rate assessment of ovarian germ cell tumors is hindered by the
fact that ovarian germ cell tumors occur much less frequently
than their testicular counterparts. Furthermore, there appears to
be significant inter-tumoral heterogeneity in the activation of these
pathways, even within tumors with similar histology (Fustino et al.,
2011).
While infrequent, we do know that malignant transformation
of germ cells often depends on the presence of genetic material
from a Y chromosome (Kota et al., 2012). The most likely candi-
date gene for dysgerminomas found in the critical region of the Y
chromosome responsible for gonadoblastoma is TSPY1 (Chand-
ley and Cooke, 1994). It has long been known that dysgerminomas
are frequently are observed in dysgenetic gonads due to the pres-
ence of all or a portion of the human Y chromosome. As many as
35 copies of the TSPY1 gene are found on the human Y chromo-
some (Manz et al., 1993). The gene product generated by TSPY1
is typically expressed only in testis and appears to be involved in
spermatogenesis. High levels of its expression have been observed
in gonadoblastomas recovered from dysgenetic patients (Hersmus
et al., 2012). However, the mechanisms by which TSPY1 expres-
sion and/or the presence of Y chromosomal material potentially
leads to ovarian germ cell tumors are unclear. Activating muta-
tions and amplification of the proto-oncogene c-kit, a growth
factor receptor, have also been reported to occur in as many as
one-third of ovarian germ cell tumors (Cheng et al., 2011). These
mutations have been associated with advanced stage disease and
may contribute to the progression of this disease. In addition,
c-kit has been shown to play an important role in regulating
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the differentiation of PGCs. Two recent genome-wide association
studies have implicated KITLG, the kit ligand, DMRT1, and SPRY3
in familial testicular cancer (Kanetsky et al., 2009; Turnbull et al.,
2010). It is possible that similar mechanisms are at work in ovarian
germ cell tumors. Lastly, recent work points to a role for dysregu-
lated miRNA expression as a potential cause of ovarian germ cell
tumors. Currently the majority of data on miRNA expression in
these tumors comes from testicular germ cell tumors. At least one
group has reported that the overexpression of miR-371 and miR-
302 miRNA families is consistently observed in ovarian germ cell
tumors (Palmer et al., 2010). Both miR-371 and miR-302 poten-
tially target a wide variety of gene products relevant to cancer
growth and metastasis. This observation is intriguing as a recent
genetic screen has identified miRNAs from the miR-371 cluster
as putative oncogenes in human germ cell tumors (Voorhoeve
et al., 2006). The investigators initially reporting these observa-
tions have followed up on this initial report, confirming that the
miR-371-373 cluster is highly expressed in seminomas, EC, and
YST of both ovarian and testicular origin (Gillis et al., 2007).
The biologic role of this cluster appears to be related to wild-
type TP53 gene activity in germ cell tumor cells, suggesting that
the capacity of this locus to regulate TP53 is a crucial player in the
pathogenesis of these tumors. Other potential roles include the
capacity of both miR-373 and miR-520c to inhibit CD44, poten-
tially promoting metastatic spread of disease spread. Other work
has recently shown that miRNA identified by these studies can also
be detected in human serum, opening the door for their poten-
tial use as diagnostic and prognostic biomarkers (Murray et al.,
2011). This creates new opportunities for evaluating therapeutic
responses or monitoring patients for recurrent disease.
FUTURE DIRECTIONS
Despite the excitement generated by the recent discovery of FOXL2
and DICER1 as key tumor suppressors in pediatric ovarian cancers,
there is still much to be understood regarding the mechanisms by
which these events lead to cancer. Answers will ultimately prove
important not only for understanding ovarian cancer but also
many other solid human tumors. For example, a number of recent
reports have found that DICER1 expression is lost in subsets of
epithelial ovarian and uterine cancers and that reduced levels of
DICER1 play a key role in determining clinical outcomes (Merritt
et al., 2008; Zighelboim et al., 2011). Germline DICER1 mutations
have also been described in a number of other rare cancers that
occur in children, such cervical embryonal rhabdomyosarcoma
and pituitary blastoma (Choong, 2012).
Determining how altered DICER1 expression and or DICER1
mutations impact miRNA expression and function as tumor sup-
pressors will be important for assessing how best this insight can
be used to develop therapeutic targets and biomarkers. Answers
to these questions may come from transgenic mice. Mice with
conditional Dicer1 knockout support the relevance of both Dicer1
and miRNAs in normal development in diverse tissues, includ-
ing the female reproductive tract (Nagaraja et al., 2008). Loss of
a single Dicer1 allele does not appear sufficient to induce cancer,
despite its ability to reduce time to tumor onset and overall sur-
vival murine models of cancer (Kumar et al., 2009). These latter
observations seem to indicate that, in mice, Dicer1 is a haplotype
insufficient tumor suppressor. In contrast, the phenotypes asso-
ciated with somatic DICER1 mutations in humans suggest these
mutations function as a dominant phenotype. However, it will
be critical to more precisely examine these questions in greater
depth. The initial reports examining DICER1 studied normal tis-
sues from only a small number of the patients (Kumar et al.,
2009). Germline mutations in DICER1 were observed in four of
these specimens, suggesting that DICER1 mutations in humans
conform to the traditional two-hit model of carcinogenesis. Ulti-
mately, resolution of this question will require examining germline
DNA in addition to tumor DNA across a much larger panel of
patients.
Effective utilization of recent discoveries may also require that
we broaden the scope of our search to better understand how
altered DICER1 expression and function may play a role in car-
cinogenesis. A recent study using Amhr2-Cre/Dicer fl/fl mice has
shown that complete Dicer1 loss, when combined with PTEN
knockout in Müllerian-derived cells, leads poorly differentiated
tumors that in the oviduct (Kim et al., 2012a,b). However, tumors
that develop in this model appear to originate in stromal cells of
the tube, rather than tubal epithelia, ovarian stroma, granulosa
cells, or germ cells. This observation challenges the view that com-
plete loss of Dicer1 is lethal to tumor cells. It also underscores the
need to learn how dysregulated activity in other pathways involved
in miRNA biogenesis may be potentially involved in pediatric and
other cancers (Yang and Lai, 2011). As discussed above, several of
the DICER1 mutations observed in pediatric ovarian cancers have
been shown to disrupt rather than suppress normal patterns of
miRNA expression. Understanding how the miRNA landscape is
shifted from a tumor suppressive to oncogenic milieu will ulti-
mately be important for determining how the insights discussed
above can be best applied clinically.
It will also likely be important to recognize the impact of
DICER1 mutations in pediatric ovarian cancers could be much
more complex than a simple gain or loss of function. Recent
evidence indicates that disease states can lead to non-templated
addition of nucleotides to mature human miRNAs that impact
function (Guo et al., 2011). However, when combined with insight
into the genetic context in which these alterations lead to cancer,
such knowledge would open the door to miRNA-based therapies
that could be used in a highly specific and rationale manner to
either reverse or prevent these diseases. Similarly, many questions
remain unsettled regarding the role of FOXL2 in pediatric ovarian
cancers. Perhaps foremost of these is how the mutations identified
impact FOXL2 function. Given the central role in forkhead domain
transcription factors in regulating diverse functions within nor-
mal ovary as well as the proliferation, metabolism, and apoptosis,
efforts to dissect the cell-specific role of this transcription factor
will likely shed significant insight into normal ovarian develop-
ment, as well as the mechanisms by which the dysregulated activity
of these cells leads to a cancer.
Efforts to explore other mechanisms potentially contributing
to the pathogenesis of both ovarian germ cell and sex-cord-
stromal tumors should not be neglected. For example, mul-
tiple mechanisms could conceivably lead to altered DICER1
expression or function in pediatric ovarian cancers in addition
to recently identified mutations. For example, work examining
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transcriptional profiles generated for epithelial ovarian cancers by
the Cancer Genome Atlas consortium (TCGA) has been unable
to confirm that levels of DICER1 transcript are decreased in
epithelial ovarian cancers (Creighton et al., 2012). This obser-
vation is curious, as reduced expression of DICER1 protein
has notably reported to determine ovarian cancer outcomes
(Merritt et al., 2008). This discrepancy could be explained if
DICER1 expression is largely regulated by epigenetic events
that suppress translation of DICER1 mRNA in a subset of
cancers, leaving transcript levels unchanged. Similar mecha-
nisms could contribute to the pathogenesis of Sertoli–Leydig cell
tumors or other categories of pediatric sex-cord-stromal tumors
where germline or somatic DICER1 mutations have not been
observed.
Ultimately, the greatest challenge for utilizing recent insights
into the biology of pediatric ovarian cancers will be to create
rationale for effective treatments. Attempts to replace the activ-
ity of dysfunctional tumor suppressors, such as TP53, have been
largely ineffective. For this reason, replacement or targeting of
key miRNAs or downstream transcriptional targets whose expres-
sion is altered by DICER1 and FOXL2 mutations may be the
most efficient route to clinical success (Bader et al., 2011). How-
ever, even in the case of TP53, a number of recent reports have
identified novel approaches to overcome the adverse impact of
a dominant dysfunctional gene product (Pruschy et al., 2001).
Thus, it may be possible to adopt similar strategies for overcoming
cancer-associated mutations in DICER1 or FOXL2.
Even under circumstances where it may not be possible to effec-
tively manipulate DICER1 for adequate therapeutic advantage, it
may be possible to target specific miRNAs. One of the important
aspects of recent work examining the role of DICER1 muta-
tions in carcinogenesis has been the discovery that a reduction
in DICER1 expression does not uniformly impact the expres-
sion of all miRNAs. Thus, it may be possible to identify one or
more individual miRNAs whose expression can be specifically
targeted for therapeutic purposes in tumors with DICER1 muta-
tions. Although early results have been encouraging, the concept
of targeting miRNAs will likely prove to be a significant chal-
lenge as well. A number of recent papers have demonstrated that
anti-sense miRNA oligonucleotides (AMO) can be used to down-
regulate oncogenic miRNAs and silence them (Weiler et al., 2006).
Another promising therapeutic approach would be to directly
deliver synthetic mimics for key tumor suppressor miRNAs to
tumor tissue where the expression of these miRNAs has been lost.
Lastly, miRNAs differentially expressed in pediatric ovarian can-
cers RNA expression profiles can also be potentially diagnostic
markers. MiRNA microarray analysis is a valuable technique that
highlights aberrant miRNA expression even in poorly differen-
tiated cancer cells. Similarly knowing the expression profile can
determine response to therapy, predict patient survival, and dis-
tinguish more aggressive or resistant cancer subtypes. Fortunately,
the recent insights discussed here have placed us well along the
path toward improving outcomes for children diagnosed with one
of these cancers.
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